专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20120214200A1 PROKARYOTIC EXPRESSION CONSTRUCT 有权
标题翻译：原型表达式结构
公开(公告)号：US20120214200A1
公开(公告)日：2012-08-23
申请号：US13217537
申请日：2011-08-25
申请人： Adelbert Grossmann , Friedrich Hesse , Erhard Kopetzki , Wilma Lau , Christian Schantz
发明人： Adelbert Grossmann , Friedrich Hesse , Erhard Kopetzki , Wilma Lau , Christian Schantz
IPC分类号： C12P21/02 , C12N1/21 , C07K19/00 , C12N15/62
CPC分类号： C12N15/62 , C07K14/775 , C07K2319/02 , C07K2319/21 , C07K2319/50 , C07K2319/70 , C12N15/70 , C12P21/02 , C12P21/06
摘要： A pro-polypeptide which is useful for the expression of a polypeptide of interest in a prokaryotic cell. Therefore the pro-polypeptide is fused to the N-terminus of the polypeptide of interest. The pro-polypeptide as reported herein provides for improved expression yields and improves the handling of the fusion polypeptide (downstream processing, purification). For example, efficient endotoxin removal is effected while the protein of interest comprising the pro-polypeptide is bound e.g. to an affinity chromatography material. Thereafter the pro-polypeptide can efficiently be cleaved from the polypeptide of interest by the incorporated protease cleavage site with the cognate protease.
摘要翻译：可用于在原核细胞中表达目的多肽的原多肽。因此，原多肽与感兴趣的多肽的N末端融合。本文报道的前多肽提供改善的表达产率并改善融合多肽的处理（下游处理，纯化）。例如，有效的内毒素去除被实现，而包含前多肽的目的蛋白质被结合例如。至亲和层析材料。此后，通过与同源蛋白酶合并的蛋白酶切割位点，可以有效地从所述多肽切割所述多肽。

12. 发明申请

US20110165182A1 CONJUGATE OF AN ANTIBODY AGAINST CCR5 AND AN ANTIFUSOGENIC PEPTIDE 审中-公开
标题翻译：抗CCR5抗原肽和抗原肽的抗体结合
公开(公告)号：US20110165182A1
公开(公告)日：2011-07-07
申请号：US13050615
申请日：2011-03-17
申请人： Michael Brandt , Stephan Fischer , Erhard Kopetzki , Suryanarayana Sankuratri , Ralf Schumacher
发明人： Michael Brandt , Stephan Fischer , Erhard Kopetzki , Suryanarayana Sankuratri , Ralf Schumacher
IPC分类号： A61K39/395 , C07K19/00 , A61P31/18 , A61P31/12
CPC分类号： C07K16/2866 , C07K14/005 , C07K2319/00 , C12N2740/16122
摘要： The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.
摘要翻译：本发明涉及包含一种或多种抗融合肽和抗CCR5抗体（mAb CCR5）的缀合物，其特征在于，一至八个抗融合肽各自与所述抗 - 抗体的重链和/或轻链的一个末端缀合， CCR5抗体和所述缀合物的药物用途。

13. 发明授权

US07951920B2 Conjugate of an antibody against CCR5 and an antifusogenic peptide 失效
标题翻译：抗CCR5抗体和抗融合肽的缀合物
公开(公告)号：US07951920B2
公开(公告)日：2011-05-31
申请号：US11893899
申请日：2007-08-17
申请人： Michael Brandt , Stephan Fischer , Erhard Kopetzki , Suryanarayana Sankuratri , Ralf Schumacher
发明人： Michael Brandt , Stephan Fischer , Erhard Kopetzki , Suryanarayana Sankuratri , Ralf Schumacher
IPC分类号： C07K17/00 , C07K17/14 , C12P21/08 , A61K39/00
CPC分类号： C07K16/2866 , C07K14/005 , C07K2319/00 , C12N2740/16122
摘要： The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.
摘要翻译：本发明涉及包含一种或多种抗融合肽和抗CCR5抗体（mAb CCR5）的缀合物，其特征在于，一至八个抗融合肽各自与抗-CD5抗体的重链和/或轻链的一个末端缀合， CCR5抗体和缀合物的药物用途。

14. 发明授权

US07807409B2 Method for the recombinant expression of a polypeptide 有权
标题翻译：重组表达多肽的方法
公开(公告)号：US07807409B2
公开(公告)日：2010-10-05
申请号：US11583573
申请日：2006-10-19
申请人： Erhard Kopetzki
发明人： Erhard Kopetzki
IPC分类号： C12N15/00 , C12N15/63
CPC分类号： C07K14/005 , A61K38/162 , C07K16/00 , C07K16/2863 , C07K2317/50 , C07K2319/00 , C12N2740/16122
摘要： A method for the recombinant production of a heterologous polypeptide in a eukaryotic host cell is described. The host cell comprises an expression plasmid, whereby the expression plasmid comprises in a 5′ to 3′ direction a) a promoter, b) a nucleic acid encoding a first polypeptide, whose amino acid sequence is selected from Table 1 depending on the first two amino acids of the second polypeptide, c) a nucleic acid encoding a second polypeptide comprising a nucleic acid encoding a heterologous polypeptide, a nucleic acid encoding a linker, and a nucleic acid encoding an immunoglobulin fragment, and d) a 3′ untranslated region comprising a polyadenylation signal. Further a plasmid and a kit are described.
摘要翻译：描述了在真核宿主细胞中重组产生异源多肽的方法。宿主细胞包含表达质粒，其中表达质粒包含5'至3'方向a）启动子，b）编码第一多肽的核酸，其氨基酸序列选自表1，取决于前两个第二多肽的氨基酸，c）编码包含编码异源多肽的核酸，编码接头的核酸和编码免疫球蛋白片段的核酸的第二多肽的核酸，以及d）3'非翻译区，其包含多聚腺苷酸化信号。此外，还描述了质粒和试剂盒。

15. 发明申请

US20100249379A1 PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS 有权
标题翻译：来自多种核酸的蛋白质表达
公开(公告)号：US20100249379A1
公开(公告)日：2010-09-30
申请号：US12681781
申请日：2008-10-09
申请人： Ulrich Goepfert , Hendrik Knoetgen , Erhard Kopetzki , Anne Stern
发明人： Ulrich Goepfert , Hendrik Knoetgen , Erhard Kopetzki , Anne Stern
IPC分类号： C07K16/28 , C12P21/08
CPC分类号： C12N15/85 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K2317/14 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C12P21/00
摘要： The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfecting said selected CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a second eukaryotic selection agent different to said first eukaryotic selection agent, d) selecting a CHO cell by selected growth in cultivation medium containing said first and said second eukaryotic selection agent, iv) cultivating said transfected CHO cell in a medium in the presence of said first and second eukaryotic selection agent, under conditions suitable for the expression of said second, and third nucleic acid, and v) recovering said secreted heterologous immunoglobulin from the cultivation medium.
摘要翻译：本发明报告了在CHO细胞中重组产生分泌的异源免疫球蛋白的方法，其包括以下步骤：i）提供适于在悬浮培养物中生长的CHO细胞，适于在无血清培养基中生长，支原体免费和无病毒，ii）提供包含原核复制起点的载体，赋予原核选择剂抗性的第一核酸，编码所述异源免疫球蛋白的重链的第二核酸，编码光的第三核酸所述异源免疫球蛋白链，赋予对真核选择剂的抗性的第四核酸，iii）转染所述CHO细胞，其中所述转染包括a）用包含第四核酸的所述载体转染所述CHO细胞，所述第四核酸赋予对第一真核选择性的抗性试剂，b）通过在含有所述第一种真核生物的培养基中生长来选择CHO细胞 c）用所述载体转染所述选择的CHO细胞，所述载体包含赋予与所述第一真核选择试剂不同的第二真核选择剂的抗性的第四核酸，d）通过在含有所述第一和第二真核选择试剂的培养基中选择生长来选择CHO细胞，所述第二真核选择剂，iv）在所述第一和第二真核选择剂的存在下，在适于表达所述第二和第三核酸的条件下，在培养基中培养所述转染的CHO细胞，和v）回收所述分泌的异源免疫球蛋白。

16. 发明申请

US20100184144A1 IMMUNOGLOBULIN PRODUCTION 有权
标题翻译：免疫球蛋白生产
公开(公告)号：US20100184144A1
公开(公告)日：2010-07-22
申请号：US12664401
申请日：2008-06-25
申请人： Ulrich Goepfert , Silke Hansen , Hendrik Knoetgen , Erhard Kopetzki , Oliver Ploettner
发明人： Ulrich Goepfert , Silke Hansen , Hendrik Knoetgen , Erhard Kopetzki , Oliver Ploettner
IPC分类号： C12P21/00 , C07H21/00 , C12N15/74 , C12N5/10
CPC分类号： C07K16/00 , C07K2317/21 , C07K2317/52 , C12N2830/42
摘要： The current invention comprises a nucleic acid encoding the amino acid sequence of the C-terminal part of the CH3-domain of an immunoglobulin of the class IgA or IgG, or the C-terminal part of the CH4-domain of an immunoglobulin of the class IgE or IgM, wherein the glycine-lysine-dipeptide comprised in the amino acid sequence of the C-terminal part of the CH3- or CH4-domain is encoded by the nucleic acid ggaaaa, or the nucleic acid ggcaaa, or the nucleic acid gggaaa, or the nucleic acid gggaag, or the nucleic acid ggcaag, or the nucleic acid ggaaag.
摘要翻译：本发明包括编码IgA或IgG类免疫球蛋白的CH3结构域的C末端部分的氨基酸序列的核酸，或类别的免疫球蛋白的CH4结构域的C末端部分 IgE或IgM，其中包含在CH 3 - 或CH 4结构域的C-末端部分的氨基酸序列中的甘氨酸 - 赖氨酸二肽由核酸ggaaaa或核酸ggcaaa或核酸gggaaa ，或核酸gggaag，或核酸ggcaag，或核酸ggaaag。

17. 发明授权

US07563441B2 Anti-P-selectin antibodies 有权
标题翻译：抗P-选择素抗体
公开(公告)号：US07563441B2
公开(公告)日：2009-07-21
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译：本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。

18. 发明申请

US20090028881A1 Conjugate of an antibody against CCR5 and an antifusogenic peptide 失效
标题翻译：抗CCR5抗体和抗融合肽的缀合物
公开(公告)号：US20090028881A1
公开(公告)日：2009-01-29
申请号：US11893899
申请日：2007-08-17
申请人： Michael Brandt , Stephan Fischer , Erhard Kopetzki , Suryanarayana Sankuratri , Ralf Schumacher
发明人： Michael Brandt , Stephan Fischer , Erhard Kopetzki , Suryanarayana Sankuratri , Ralf Schumacher
IPC分类号： C07K16/46 , A61K39/395 , C12P21/08 , A61P31/12 , A61P31/18
CPC分类号： C07K16/2866 , C07K14/005 , C07K2319/00 , C12N2740/16122
摘要： The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.
摘要翻译：本发明涉及包含一种或多种抗融合肽和抗CCR5抗体（mAb CCR5）的缀合物，其特征在于，一至八个抗融合肽各自与所述抗 - 抗体的重链和/或轻链的一个末端缀合， CCR5抗体和所述缀合物的药物用途。

19. 发明授权

US5602018A Hypoglycosylated recombinant glucose oxidases 失效
标题翻译：低聚糖重组葡萄糖氧化酶
公开(公告)号：US5602018A
公开(公告)日：1997-02-11
申请号：US374770
申请日：1995-02-07
申请人： Erhard Kopetzki , Klaus Lehnert
发明人： Erhard Kopetzki , Klaus Lehnert
IPC分类号： G01N33/535 , C07K14/37 , C07K14/38 , C07K14/41 , C12N9/04 , C12N15/09 , C12N15/53 , C12Q1/26 , C12R1/685 , C12R1/865 , C12N1/14 , C12P21/06
CPC分类号： C12N9/0006
摘要： Hypoglycosylated recombinant glucose oxidase with a molecular weight of ca. 68-80 kDa, a specific activity of ca. 200 U/mg unit of weight, a carbohydrate portion of ca. 12% which is obtainable by expression of a recombinant DNA containing the GOD gene in the N-glycosylation-defective yeast mutants DSM 7042, DSM 7338, DSM 7160 or DSM 7340 or allelic mutant strains, fermentation and isolation of the enzyme from the culture supernatant or the cells.
摘要翻译： PCT No.PCT / EP93 / 02054 Sec。 371日期：1995年2月7日 102（e）日期1995年2月7日PCT提交1993年8月2日PCT公布。公开号WO94 / 03608 日期：1994年2月17日分子量约为的低聚糖重组葡萄糖氧化酶 68-80 kDa，比活性约为 200 U / mg单位重量，碳水化合物部分约通过在N-糖基化缺陷型酵母突变体DSM 7042，DSM 7338，DSM 7160或DSM 7340或等位基因突变株中表达含有GOD基因的重组DNA获得的12％，可以从培养上清液中发酵和分离酶或细胞。

20. 发明授权

US5434067A Process for the production and renaturation of recombinant, biologically active, eukaryotic alkaline phosphatase 失效
标题翻译：重组，生物活性的真核碱性磷酸酶的生产和复性的方法
公开(公告)号：US5434067A
公开(公告)日：1995-07-18
申请号：US100124
申请日：1993-07-30
申请人： Uwe Michaelis , Rainer Rudolph , Michael Jarsch , Erhard Kopetzki , Helmut Burtscher , Gether Schumacher
发明人： Uwe Michaelis , Rainer Rudolph , Michael Jarsch , Erhard Kopetzki , Helmut Burtscher , Gether Schumacher
IPC分类号： C07K1/107 , C12N9/16 , C12N9/96 , C12N15/09 , C12N15/55 , C12N15/70 , C12R1/19 , C12N9/12 , C07K1/36 , C12N15/54
CPC分类号： C12N9/16
摘要： In a process for the production of recombinant, biologically active, eukaryotic alkaline phosphatase a DNA sequence coding for a eukaryotic alkaline phosphatase is expressed in a prokaryotic host cell and the expression product is obtained in an active form by cell lysis, solubilization under denaturing conditions and subsequent renaturation. In this process the renaturation step is carried out in the presence of one or several stabilizing agents.
摘要翻译：在生产重组，生物活性的真核碱性磷酸酶的过程中，在原核宿主细胞中表达编码真核碱性磷酸酶的DNA序列，通过细胞裂解，在变性条件下溶解获得活性形式的表达产物，随后复性。在该方法中，复性步骤在一种或几种稳定剂的存在下进行。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式